Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Merck launches MILLIPLEX Immunoassays for COVID-19 research

Products are for professional/laboratory use only. 

The SARS-CoV-2 coronavirus contains 4 major structural proteins, Spike (S), Nucleocapsid (N), Membrane (M), and Envelope (E). S, M, and E proteins form the viral coat, and the N protein packages the RNA genome. The Spike protein includes three subunits, S1, S2 and the receptor binding domain (RBD). The virus‘ RBD binds to ACE2 receptors of human cells. The virus then enters the cell, takes over the cellular machinery, reproduces, and the viral contagion continues.

After infection, the body’s immune system can mount a defense by producing three major antibody types, immunoglobulin M (IgM), immunoglobulin G (IgG), and immunoglobulin A (IgA). IgM forms the very early response to an infectious agent but also fades more rapidly. IgG response forms somewhat later but can confer a long lasting immunity to an infectious agent. While IgM and IgG are humoral immune responses, IgA is a mucosal immune response. IgA is found in blood plasma and serum.

Performing IgM, IgG, and IgA blood-based serology testing may help identify people who have been exposed to SARS-CoV-2, and who have generated some level of immune response. By testing the response of each immunoglobulin type against specific antigenic regions of the SARS-CoV-2 virus, researchers may further understand the immune response to the virus over the course of infection and recovery from COVID-19.

Here we introduce three separate MILLIPLEX® assays, one for each immunoglobulin type, IgM, IgG and IgA.

  • MPHC19SERM185K, MILLIPLEX® SARS-CoV-2 Antigen Panel 1 IgM
  • MPHC19SERG185K, MILLIPLEX® SARS-CoV-2 Antigen Panel 1 IgG
  • MPHC19SERA185K, MILLIPLEX® SARS-CoV-2 Antigen Panel 1 IgA

Each configurable 4-plex panel allows the researcher to select any or all the following viral antigens:

  • SARS-CoV-2 S1
  • SARS-CoV-2 S2
  • SARS-CoV-2 RBD
  • SARS-CoV-2 N

Discover Merck MILLIPLEX Products

Download Latest Analyte Update >



Request a Quote

Request Quote

Recent Posts

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article

Merck FemtoQuest™

Gain your desired immunoassay sensitivity with the ultrasensitive FemtoQuest™ system Measure down to femtogram/mL levels Improved precision and robust data Perform dual-plex and single analyte…

Read full article